The National Institute for Health and Care Excellence (NICE) has approved the use of Enhertu in England, marking a significant shift after an earlier refusal.
This decision follows two key modifications to the assessment process that altered the financial calculus regarding the drug's value.
One factor was a change in how quality of life is quantified for patients, with NICE increasing the threshold it is willing to pay per Quality-Adjusted Life Year from £30,000 to £35,000.
The second element involved a trade arrangement between the UK government and the United States, which included an agreement to spend 25% more on certain medicines.
These adjustments were sufficient to reverse the previous outcome, according to reports from The BBC.
The medication in question is capable of extending life by approximately seven months on average for those with HER2-low metastatic breast cancer affecting the bones and lungs.
Enhertu has already been prescribed in Scotland for over two years and remains available there.
Individuals affected by the condition often maintain active social lives, though medical appointments remain a regular part of their routine.